Christine Garcia1, Carolyn Lefkowits2, Elizabeth Pelkofski3, Leslie Blackhall4, Linda R Duska5. 1. Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, United States. Electronic address: cg5zc@virginia.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, United States; Section of Palliative Care, Division of General of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, United States. 3. Division of Gynecologic Oncology, Baptist Health Lexington, Lexington, KY, United States. 4. Section of Palliative Care, University of Virginia, Charlottesville, VA, United States. 5. Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, United States.
Abstract
OBJECTIVE: To characterize risk for opioid misuse among gynecologic oncology patients. METHODS: The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. RESULTS: A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancer patients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancer patients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). CONCLUSIONS: Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancer patients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.
OBJECTIVE: To characterize risk for opioid misuse among gynecologic oncology patients. METHODS: The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. RESULTS: A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancerpatients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancerpatients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). CONCLUSIONS: Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancerpatients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.
Authors: Robyn Keall; Paul Keall; Carly Kiani; Tim Luckett; Richard McNeill; Melanie Lovell Journal: Support Care Cancer Date: 2022-02-15 Impact factor: 3.359
Authors: Ritu Arya; Daniel Hong; Olivia Schultz; Jessica M Jutzy; Katherine Cotangco; Pamela Peters; Ellen W Daily; Anne R McCall; Andrew R Howard; Yasmin Hasan; Rajul Kothari; Christina H Son Journal: Adv Radiat Oncol Date: 2021-10-20